Updates on Lifestyle-Related Diseases and Bone Metabolism. Effects of therapeutic agents for lifestyle-related diseases on osteoporosis

Nobuki Hayakawa, Atsushi Suzuki

研究成果: Article

1 引用 (Scopus)

抄録

It has been revealed that various therapeutic agents for lifestyle-related diseases could affect bone metabolism. For example, thiazolidines, loop diuretics and warfarin would be possibly disadvantageous to bone metabolism. In many cases with lifestyle-related disease, it is necessary to take the medicine over a long term. Therefore, we should pay enough attention to bone metabolism during the selection of medicine, especially in the treatment of a high risk group for bone fracture. However, a majority of these drugs lack the evidence with randomized controlled trials for osteoporotic fracture. Further clinical research should be required to clarify the impact of each drug on osteoporosis with lifestyle-related diseases.

元の言語English
ページ(範囲)1661-1669
ページ数9
ジャーナルClinical calcium
24
発行部数11
出版物ステータスPublished - 01-11-2014

Fingerprint

Bone Diseases
Therapeutic Uses
Osteoporosis
Life Style
Bone and Bones
Medicine
Thiazolidines
Sodium Potassium Chloride Symporter Inhibitors
Osteoporotic Fractures
Bone Fractures
Warfarin
Pharmaceutical Preparations
Randomized Controlled Trials
Research
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

これを引用

@article{d65b83ed3f584669bea0215604a318fe,
title = "Updates on Lifestyle-Related Diseases and Bone Metabolism. Effects of therapeutic agents for lifestyle-related diseases on osteoporosis",
abstract = "It has been revealed that various therapeutic agents for lifestyle-related diseases could affect bone metabolism. For example, thiazolidines, loop diuretics and warfarin would be possibly disadvantageous to bone metabolism. In many cases with lifestyle-related disease, it is necessary to take the medicine over a long term. Therefore, we should pay enough attention to bone metabolism during the selection of medicine, especially in the treatment of a high risk group for bone fracture. However, a majority of these drugs lack the evidence with randomized controlled trials for osteoporotic fracture. Further clinical research should be required to clarify the impact of each drug on osteoporosis with lifestyle-related diseases.",
author = "Nobuki Hayakawa and Atsushi Suzuki",
year = "2014",
month = "11",
day = "1",
language = "English",
volume = "24",
pages = "1661--1669",
journal = "Clinical calcium",
issn = "0917-5857",
publisher = "Iyaku (Medicine & Drug) Journal Co",
number = "11",

}

TY - JOUR

T1 - Updates on Lifestyle-Related Diseases and Bone Metabolism. Effects of therapeutic agents for lifestyle-related diseases on osteoporosis

AU - Hayakawa, Nobuki

AU - Suzuki, Atsushi

PY - 2014/11/1

Y1 - 2014/11/1

N2 - It has been revealed that various therapeutic agents for lifestyle-related diseases could affect bone metabolism. For example, thiazolidines, loop diuretics and warfarin would be possibly disadvantageous to bone metabolism. In many cases with lifestyle-related disease, it is necessary to take the medicine over a long term. Therefore, we should pay enough attention to bone metabolism during the selection of medicine, especially in the treatment of a high risk group for bone fracture. However, a majority of these drugs lack the evidence with randomized controlled trials for osteoporotic fracture. Further clinical research should be required to clarify the impact of each drug on osteoporosis with lifestyle-related diseases.

AB - It has been revealed that various therapeutic agents for lifestyle-related diseases could affect bone metabolism. For example, thiazolidines, loop diuretics and warfarin would be possibly disadvantageous to bone metabolism. In many cases with lifestyle-related disease, it is necessary to take the medicine over a long term. Therefore, we should pay enough attention to bone metabolism during the selection of medicine, especially in the treatment of a high risk group for bone fracture. However, a majority of these drugs lack the evidence with randomized controlled trials for osteoporotic fracture. Further clinical research should be required to clarify the impact of each drug on osteoporosis with lifestyle-related diseases.

UR - http://www.scopus.com/inward/record.url?scp=85016506987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016506987&partnerID=8YFLogxK

M3 - Article

C2 - 25355150

AN - SCOPUS:85016506987

VL - 24

SP - 1661

EP - 1669

JO - Clinical calcium

JF - Clinical calcium

SN - 0917-5857

IS - 11

ER -